| Title |
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, April 2017
|
| DOI | 10.2147/dddt.s110209 |
| Pubmed ID | |
| Authors |
Vyshak Alva Venur, Monika Joshi, Kenneth G Nepple, Yousef Zakharia |
| Abstract |
Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 25% |
| Student > Postgraduate | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Other | 3 | 9% |
| Researcher | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 10 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Environmental Science | 1 | 3% |
| Chemical Engineering | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 9 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#8,537,346
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#642
of 2,268 outputs
Outputs of similar age
#127,602
of 323,961 outputs
Outputs of similar age from Drug Design, Development and Therapy
#22
of 59 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,961 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.